162046-58-4

Basic information

• Product Name: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID
• Synonyms: TRANS-4-(TERT-BUTYLOXYCARBONYLAMINOMETHYL)-CYCLOHEXANOIC ACID;4-(TERT-BUTOXYCARBONYLAMINO-METHYL)-CYCLOHEXANECARBOXYLIC ACID;IFLAB-BB F2108-0060;BOC-AMC-OH;BOC-4-AMC-OH;BUTTPARK 52\04-68;TRANS-4-(T-BUTYLOXYCARBONYLAMINOMETHYL)-CYCLOHEXANOIC ACID;N-tert-Butoxycarbonyl-4-(aminomethyl)-cyclohexanecarboxylic acid
• CAS NO: 162046-58-4
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.33
• Product Categories: Amino Acids
• Mol File: 162046-58-4.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 410 °C at 760 mmHg
• Flash Point: 201.8 °C
• Appearance: /
• Density: 1.096 g/cm³
• Vapor Pressure: 7.17E-08mmHg at 25°C
• Refractive Index: 1.482
• Storage Temp.: Store at 0°C
• Solubility: Chloroform, Ethyl Acetate
• CAS DataBase Reference: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID(162046-58-4)
• EPA Substance Registry System: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID(162046-58-4)

Safety Data

• Hazardous Substances Data: 162046-58-4(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

4-[[(t-Butoxycarbonyl)amino]methyl]cyclohexanecarboxylic Acid is an intermediate in synthesizing cis-Tranexamic Acid (T714500), which is antifibrinolytic agent; blocks lysine binding sites of plasminogen. Hemostatic.

InChI:InChI=1/C13H23NO4/c1-13(2,3)18-12(17)14-8-9-4-6-10(7-5-9)11(15)16/h9-10H,4-8H2,1-3H3,(H,14,17)(H,15,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1197-17-7 4-aminomethyl-cyclohexanecarboxylic acid 
• 123-91-1 1,4-dioxane 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 

Downstream Products

• 1018674-46-8 trans-(4-Hydroxymethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester 
• 914645-16-2 (S)-{[4-({[2-(1-isobutoxy-ethoxycarbamoyl)-benzo[b]thiophen-6-ylmethyl]-amino}-methyl)-cyclohexylmethyl]-amino}-phenyl-acetic acid tert-butyl ester 
• 914645-11-7 (S)-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl]-amino}-phenyl-acetic acid cyclopentyl ester 
• 914645-15-1 (S)-{[4-(tert-butoxycarbonylamino-methyl)-cyclohexylmethyl]-amino}-phenyl-acetic acid tert-butyl ester 
• 914645-12-8 (S)-[(4-aminomethyl-cyclohexylmethyl)-amino]-phenyl-acetic acid cyclopentyl ester 
• 1173932-24-5 C₂₀H₃₂N₂O₂ 
• 916210-80-5 trans-4-(N-tert-butoxycarbonylaminomethyl)cyclohexane carboxaldehyde 
• 180046-56-4 tert-butyl N-[[4-(cyanomethyl)cyclohexyl]methyl]carbamate 

Relevant articles and documents

XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS

The present invention relates to a compound having the following formula (I): (I) wherein: - R is a (C1-C6)alkyl group;- R'' is preferably H;- Ar is a (C5-C12)arylene radical;- X1 is -C(=O)- or -SO2-; and- R' is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.

VASOPRESSIN V1A ANTAGONISTS

The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V 1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.

FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): (I) [INSERTCHEMICAL STRUCTURE HERE] (V)[INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.